US 11,712,441 B2
Pharmaceutical compositions comprising meloxicam
Herriot Tabuteau, New York, NY (US)
Assigned to AXSOME THERAPEUTICS, INC., New York, NY (US)
Filed by AXSOME THERAPEUTICS, INC., New York, NY (US)
Filed on Sep. 7, 2022, as Appl. No. 17/930,272.
Application 17/930,272 is a continuation in part of application No. 17/404,129, filed on Aug. 17, 2021, granted, now 11,471,464.
Application 17/404,129 is a continuation of application No. 17/205,936, filed on Mar. 18, 2021, granted, now 11,185,550, issued on Nov. 30, 2021.
Application 17/205,936 is a continuation in part of application No. 16/857,435, filed on Apr. 24, 2020, granted, now 10,987,358, issued on Apr. 27, 2021.
Application 16/857,435 is a continuation in part of application No. 16/513,612, filed on Jul. 16, 2019, granted, now 10,688,102, issued on Jun. 23, 2020.
Application 16/513,612 is a continuation in part of application No. PCT/US2018/032162, filed on May 10, 2018.
Application PCT/US2018/032162 is a continuation in part of application No. PCT/US2018/012433, filed on Jan. 4, 2018.
Application PCT/US2018/032162 is a continuation in part of application No. 17/930,272.
Application 17/930,272 is a continuation in part of application No. 17/547,676, filed on Dec. 10, 2021, abandoned.
Application 17/547,676 is a continuation of application No. 17/122,618, filed on Dec. 15, 2020, granted, now 11,219,626, issued on Jan. 11, 2022.
Application 17/122,618 is a continuation in part of application No. PCT/US2019/040495, filed on Jul. 3, 2019.
Claims priority of provisional application 62/536,466, filed on Jul. 25, 2017.
Claims priority of provisional application 62/526,884, filed on Jun. 29, 2017.
Claims priority of provisional application 62/802,198, filed on Feb. 6, 2019.
Claims priority of provisional application 62/803,756, filed on Feb. 11, 2019.
Claims priority of provisional application 62/835,613, filed on Apr. 18, 2019.
Claims priority of provisional application 62/846,311, filed on May 10, 2019.
Claims priority of provisional application 62/693,871, filed on Jul. 3, 2018.
Prior Publication US 2023/0016504 A1, Jan. 19, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/5415 (2006.01); A61P 25/06 (2006.01); A61K 31/4196 (2006.01)
CPC A61K 31/5415 (2013.01) [A61K 31/4196 (2013.01); A61P 25/06 (2018.01)] 18 Claims
 
1. A method of treating migraine, comprising orally administering one tablet daily to a human being in need thereof, wherein the tablet comprises about 20 mg of meloxicam, or a molar equivalent amount of a salt form of meloxicam, and from about 10 mg to about 15 mg of rizatriptan, or a molar equivalent amount of a salt form of rizatriptan.